Growth Metrics

Merck (MRK) EBITDA Margin (2009 - 2026)

Merck (MRK) reported EBITDA Margin of 47.46% for Q1 2026, down 6345.0% year-over-year from 0.76% in Q1 2025, and down 265.23% on a QoQ basis from 12.99% in Q4 2025.

Merck (MRK) has 18 years of EBITDA Margin data on file, last reported at 47.46% in Q1 2026.

  • Quarterly EBITDA Margin fell 6345.0% year-over-year to 47.46% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.41% (down 1638.0% YoY) and the FY2025 annual result came in at 7.21%, down 19.0% from the prior year.
  • EBITDA Margin retreated to 47.46% in Q1 2026 per MRK's latest filing, from 12.99% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 16.73% in Q3 2025 and bottomed at 62.25% in Q2 2023.
  • The 5-year median for EBITDA Margin is 0.06% (2024), against an average of 5.39%.
  • The widest annual swing landed in 2023, when EBITDA Margin slumped 6411 bps; it then soared 7628 bps in 2024.
  • Tracing MRK's EBITDA Margin over 5 years: stood at 2.66% in 2022, then slumped by 1430 bps to 40.72% in 2023, then jumped by 105 bps to 2.19% in 2024, then slumped by 694 bps to 12.99% in 2025, then tumbled by 265 bps to 47.46% in 2026.
  • Per Business Quant, the three latest MRK EBITDA Margin figures stand at 47.46% (Q1 2026), 12.99% (Q4 2025), and 16.73% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 47.98%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 26.44%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 26.60%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -47.46%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 30.94%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 37.16%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -286.83%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 24.65%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -47.46%
Dec 31, 2025 -12.99%
Sep 30, 2025 16.73%
Jun 30, 2025 9.12%
Mar 31, 2025 16.00%
Dec 31, 2024 2.19%
Sep 30, 2024 0.06%
Jun 30, 2024 14.03%
Mar 31, 2024 13.50%
Dec 31, 2023 -40.72%
Sep 30, 2023 8.50%
Jun 30, 2023 -62.25%
Mar 31, 2023 -1.91%
Dec 31, 2022 -2.66%
Sep 30, 2022 -2.35%
Jun 30, 2022 1.86%
Mar 31, 2022 -3.26%
Dec 31, 2021 0.26%
Sep 30, 2021 13.81%
Jun 30, 2021 -12.16%
Mar 31, 2021 -1.99%
Dec 31, 2020 -69.18%
Sep 30, 2020 -2.81%
Jun 30, 2020 -0.06%
Mar 31, 2020 4.36%
Dec 31, 2019 -74.11%
Sep 30, 2019 -13.25%
Jun 30, 2019 -1.21%
Mar 31, 2019 0.14%
Dec 31, 2018 -6.23%
Sep 30, 2018 -8.84%
Jun 30, 2018 -12.72%
Mar 31, 2018 -18.32%
Dec 31, 2017 -14.96%
Sep 30, 2017 -30.09%
Jun 30, 2017 -6.82%
Mar 31, 2017 -11.09%
Dec 31, 2016 -47.72%
Sep 30, 2016 -4.95%
Jun 30, 2016 -21.07%
Mar 31, 2016 -20.92%
Dec 31, 2015 -29.70%
Sep 30, 2015 -13.54%
Jun 30, 2015 -30.12%
Mar 31, 2015 -23.21%
Dec 31, 2014 76.91%
Sep 30, 2014 -25.89%
Jun 30, 2014 -27.46%
Mar 31, 2014 -17.65%
Dec 31, 2013 -29.88%
Sep 30, 2013 -23.38%
Jun 30, 2013 -27.60%
Mar 31, 2013 -22.58%
Dec 31, 2012 -24.08%
Sep 30, 2012 -16.70%
Jun 30, 2012 -11.63%
Mar 31, 2012 -13.04%
Dec 31, 2011 -21.11%
Sep 30, 2011 -16.64%
Jun 30, 2011 -21.50%
Mar 31, 2011 -20.12%
Dec 31, 2010 -42.51%
Sep 30, 2010 -33.20%
Jun 30, 2010 -29.16%
Mar 31, 2010 5.65%
Dec 31, 2009 -17.08%
Sep 30, 2009 26.41%
Jun 30, 2009 23.45%
Mar 31, 2009 20.98%